Molecular Drivers of Metastatic Castrate-Resistant Prostate Cancer: New Roads to Resistance

Cancer Biology and Therapy - United States
doi 10.1080/15384047.2018.1449618
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

New Therapeutics to Treat Castrate-Resistant Prostate Cancer

The Scientific World Journal
BiochemistryMedicineGeneticsMolecular BiologyEnvironmental Science
2013English

Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer

Urologic Clinics of North America
Urology
2012English

Heterogeneous Ensembles for Predicting Survival of Metastatic, Castrate-Resistant Prostate Cancer Patients

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2016English

Evidence for the Efficacy of Enzalutamide in Postchemotherapy Metastatic Castrate-Resistant Prostate Cancer

Therapeutic Advances in Urology
Urology
2013English

Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer With 177 Lu-Psma-617

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2016English

Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer

Clinical Medicine Insights: Oncology
Oncology
2016English

Guidelines for the Management of Castrate-Resistant Prostate Cancer

Journal of the Canadian Urological Association
OncologyUrology
2010English

Guidelines for the Management of Castrate-Resistant Prostate Cancer

Canadian Urological Association Journal
Urology
2013English

Prognostic Value of 18f-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Docetaxel

Contrast Media and Molecular Imaging
MedicineNuclear MedicineRadiologyImaging
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy